08.10 03:25 | dpa-AFX: Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir |
02.10 16:37 | dpa-AFX: *HETERO ENTERS LICENSING AGREEMENT WITH GILEAD TO EXPAND LENACAPAVIR ACCESS FOR HIV IN 120 HIGH-INCIDENCE COUNTRIES |
02.10 15:36 | dpa-AFX: Gilead Partners 6 Pharma Cos. To Provide Generic Lenacapavir In High-incidence Countries |
02.10 14:34 | dpa-AFX: *GILEAD PARTNERS WITH SIX GENERIC MAKERS FOR ROYALTY-FREE LICENSING OF LENACAPAVIR TO BOOST HIV PREVENTION ACCESS |
24.09 10:26 | dpa-AFX: Gilead Recalls COVID-19 Drug Veklury For Injection |
12.09 14:52 | dpa-AFX: Gilead: Lenacapavir Reduces HIV Infections By 96% In PURPOSE 2 Trial |
12.09 14:42 | dpa-AFX: *GILEAD: TWICE-YEARLY LENACAPAVIR FOR HIV PREVENTION REDUCED HIV INFECTIONS BY 96% FROM SECOND PHASE 3 CLINICAL TRIAL |
10.09 14:17 | dpa-AFX: Gilead Sciences To Work With Genesis To Apply AI Platform To Discover, Advance Therapies |
10.09 14:10 | dpa-AFX: *GENESIS SECURES $35 MLN UPFRONT FROM GILEAD |
10.09 14:06 | dpa-AFX: *GILEAD AND GENESIS THERAPEUTICS TO DISCOVER AND DEVELOP NOVEL, SMALL MOLECULE THERAPIES ACROSS MULTIPLE TARGETS |
18.08 07:44 | dpa-AFX: Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out |
15.08 06:03 | dpa-AFX: Gilead Sciences' Livdelzi Receives Accelerated FDA Approval For Primary Biliary Cholangitis |
11.08 17:21 | dpa-AFX: Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray |
09.08 22:06 | MÄRKTE USA/Aktien nach Vortagsrally weiter aufwärts |
09.08 19:02 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
09.08 18:56 | MÄRKTE USA/Ruhe nach Vortagesrally - Eli Lilly erneut sehr fest |
09.08 16:02 | MÄRKTE USA/Geopolitik sorgt für Vorsicht |
09.08 15:04 | MÄRKTE USA/Wall Street mit Geopolitik im Minus gesehen |
08.08 22:44 | dpa-AFX: ROUNDUP: Gilead Sciences Q2 Profit Rises, Revises Full-year Guidance |
08.08 22:33 | dpa-AFX: Gilead Sciences Inc. Bottom Line Rises In Q2, But Misses Estimates |
|